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to purging activity, such that high cellularity (10e8 cells/ml) results
in a signiﬁcant loss (65%) of T and B cells with only 1 hr co-
incubation, raising to 85-90% at a 6 hr co-incubation. Co-incuba-
tion at a log lower cellularity results in a 20-30% T-cell loss.
ADCC is the primary purging mechanism; however, serum is
required to retain cellular viability as is DNAse to reduce cellular
clumping. Co-incubation temperature has little effect on purging,
although cellular viability is higher at 4C compared to 37C. T, B
and NK cells are sensitive to Alemtuzumab ADCC. DCs have a
lower sensitivity and there is a differential sensitivity of DC subsets
to alemtuzumab-mediated ADCC, such that CD123 DCs have a
lower sensitivity as compared to the CD11c DCs. Further, im-
mature myeloid suppressor cells (IMSCs) that are Lin-DR-
CD11b or Lin-DR-CD14-CD11b cells are refractory to alemtu-
zumab toxicity. This novel observation is of interest as IMSCs can
induce T cell tolerance and thus have the potential to control
GVHD. Critically, alemtuzumab purging of a hematopoietic stem
cell products has no effect on CD34 cell numbers and their
(CFU-c) as assessed in vitro.
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COMPARISON OF CELL DOSE AND OUTCOME FOR CORD BLOOD
TRANSPLANTATION (CBT) SOURCED FROM PLASMA DEPLETED (PD)
VERSUS RED CELL DEPLETED (RD) CORD BLOOD INVENTORIES
Wang, B.1, Tsukahara, E.1, Wu, T.1, Chow, T.1, Lin, A.2,
Gjertson, D.3, Petz, L.1, Chow, R.1,2,4 1StemCyte International Cord
Blood Center, Arcadia, CA; 2StemCyte Taiwan National Cord Blood
Center, Linkou, Taiwan; 3UCLA School of Public Health, Los Angeles,
CA; 4StemCyte Research Institute, Arcadia, CA.
To discern whether cord blood processing inﬂuences cord blood
bank (CBB) inventory cell dose and CBT outcome, we (1) per-
formed a large scale cell dose comparison of the NMDP CBBs that
practice red cell depletion (RD) versus plasma depletion (PD), (2)
performed an analysis comparing RD CBT results from an Insti-
tute of Medicine (IOM) study to audited outcome from a PD cord
blood (CB) inventory, and (3) searched the literature for outcome
of CBBs that practice PD and RD processing. Two of the CBBs in
the NMDP network practice PD processing (n10,912 CB)
whereas all others practice RD (n38,819 CB). PD processing
results in less than 1% cell loss in the discarded fraction (excluding
testing and archival samples), and various studies have reported
different recovery rates for RD; however, no data exist for a
rigorous comparison of actual inventories. Using data from
NMDP’s Cord Blood Bank Performance Report (6/30/06), the
percentage of high cell dose units among the two types of CBBs
were compared. Table 1A shows the proportion of CB with high
TNC counts was signiﬁcantly higher for PD CBU at all three
levels (p 0.0001; test for difference in proportions). To our
knowledge, this is the largest cell dose comparison of cord blood
banks.
The IOM conducted a study that analyzed the outcome of 3 large
CB inventories in order to ﬁnd determinants of engraftment and
patient survival (Gibbons 2005). The IOM study used RD CB. All
205 patients transplanted with PD CB through 5/06 with survival
and/or engraftment data were divided into three groups - alive,
dead, and engraftment failure - which were then compared to the
755 transplants from the IOM study using identical methodologies
(aliveengrafted & alive, deadengrafted & dead, and engraft-
ment failurenever engrafted). Table 1B summarizes the propor-
tion of patients in each category and chi-square test of homoge-
neity yielded a p-value of 0.002, suggesting that the PD CBT had
a signiﬁcantly higher proportion of survivors and lower proportion
of engraftment failures.
Various cord blood bank studies from the literature were also
summarized, which showed that transplants using PD CB may
have higher cell doses than those using RD CB. Moreover, various
RD CB inventories appeared to have similar outcome, which may
be different from transplants using PD CB inventories though
patient and disease proﬁles appear to match.
Cell Dose & Outcome Comparison Between PD & RD CB
Inventories
Table 1A NMDP PD CBB NMDP RD CBB
Test
for
Difference
CBU with
TNC
# & % of PD CB # & % of RD CB in Proportions
>125 107 3,772 (35%) 8,172 (21%) p < 0.0001
>150 107 2,157 (20%) 3,871 (10%) p < 0.0001
>200 107 703 (6%) 822 (2%) p < 0.0001
Table 1B # & % Alive # & % Dead
# & % Engraftment
Failure
PD CB 116(56.6%) 47(22.9%) 42(20.5%)
IOM CB 323(42.8%) 214(28.3%) 218(28.9%)
HEMATOPOIESIS/MESENCHYMAL CELLS
114
TRANSPLANTATION OF VASCULAR ENDOTHELIAL CELLS MEDIATES
THE HEMATOPOIETIC RECOVERY AND SURVIVAL OF IRRADIATED MICE
Muramoto, G.G.1, Himburg, H.1, Salter, A.1, Meadows, S.1, Chen, B.1,
Rickman, D.1, Chao, N.J.1, Chute, J.P.1 1Duke University Medical
Center, Durham, NC.
During embryogenesis, Flk-1 endothelial precursors contrib-
ute critically to the deﬁnitive onset of hematopoiesis. Adult sources
of endothelial cells have also been shown to support the expansion
of hematopoietic stem cells in vitro. However, the in vivo contri-
bution of vascular endothelial cells to adult hematopoiesis has been
less well characterized. In this study, we sought to determine
whether transplantation of primary endothelial cells could enhance
the hematopoietic recovery and survival of lethally irradiated mice.
C57BL/6J mice were given sublethal (700 cGy) or lethal (1050
cGy) irradiation and subsequently transplanted with murine brain-
derived ECs (MBECs) or fetal blood-derived ECs (FBECs) for 5
days. Mice transplanted with MBECs alone demonstrated acceler-
ated BM cellular recovery, radioprotection of BM c-kitsca-1-lin-
progenitors and enhanced regeneration of c-kitsca-1lin-(KSL)
stem/progenitor cells following irradiation compared to controls.
MBEC transplantation also facilitated the recovery of circulating
white blood cells and platelet counts following radiation exposure.
Remarkably, 57% of mice transplanted with MBECs survived
long-term (60 days) following 1050 cGy irradiation, which was
100% lethal in control mice. Irradiated mice that were trans-
planted with FBECs also showed signiﬁcantly increased survival,
although these animals did not survive long-term. Conversely,
transplantation with mesenchymal stem cells (MSCs) had no im-
pact on the survival of irradiated mice, suggesting that an endo-
thelial cell-speciﬁc activity accounted for the observed effects.
These data suggest that vascular endothelial cells can mediate
hematopoietic recovery following myeloablative injury and that
transplantation of endothelial cells alone can improve the survival
of lethally irradiated animals.
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MESENCHYMAL STEM CELLS ARE EFFECTIVE AT PREVENTING BUT
NOT AT TREATING GVJD
Tisato, V.1, Naresh, K.2, Navarrete, C.3, Dazzi, F.1 1Departmento of
Haematology - Imperial College, London, United Kingdom; 2Depart-
ment of Pathology - Imperial College, London, United Kingdom; 3Na-
tional Blood Service, London, United Kingdom.
Mesenchymal stem cells (MSC) are progenitor cells of stromal
origin which can differentiate into multiple lineages. MSC also
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possess immunosuppressive properties by selectively halting im-
mune cells at the G0-G1 phase of the cell cycle but only partially
affecting their effector function (split anergy). For these reasons
MSC have been used to manipulate graft-versus-host disease
(GvHD). We tested the therapeutic potentials of human MSC to
prevent and/or treat GvHD in a xenogeneic model. Sublethally
irradiated NOD/SCID mice were transplanted with CFSE-la-
belled human PBMC obtained from normal buffy coats. In a group
of mice MSC were given in a single infusion at the time of PBMC
infusion whilst in another group MSC were administered at weekly
intervals. Recipient mice were evaluated at serial intervals for
human T cells proliferation as measured by CFSE staining and
number of CD45/CD3 cells; clinical signs of GvHD (wasting,
rufﬂed hair, hunched back) were also monitored. At the end of the
experiment lymphoid and non lymphoid tissues were examined by
histological analysis. In control mice, the proliferation of human T
cells was already evident in the peripheral blood 3 weeks after
infusion and progressed thereafter. The mice started to develop
signs of GvHD after 8-10 weeks and the disease was then con-
ﬁrmed by histology. Lymphoid inﬁltrates were evident in lym-
phoid tissues as well as in liver, kidney, spleen, lung, and peritoneal
washing. The mice injected with a single dose of MSC at the time
of PBMC infusion did not behave differently form the controls.
However, when MSC were given at weekly intervals, there was a
marked decrease in human T cell engraftment and none of the
mice developed GvHD. If MSC were administered when GvHD
had already developed, T cell expansion and the course of the
disease were comparable to controls. MSC were tracked 10 days
after infusion by using cells which had been transduced with eGFP.
PCR analysis showed their presence only in the BM in mice
receiving only PBMC, but were distributed also in the lungs, liver
and peritoneal washing in the mice in which MSC were adminis-
tered with PBMC. Our study shows that the frequent administra-
tions of MSC prevent the development of GVHD but fails to treat
the disease when established. These ﬁndings are consistent with
the notion that the immunosuppressive effect of MSC resembles
split anergy, thus supporting the use of MSC as a prophylactic
rather than a therapeutic agent for GvHD.
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MULTIPOTENTIAL MESENCHYMAL STROMAL CELLS (MMSC) ABRO-
GATE ACUTE GRAFT-VERSUS-HOST DISEASE IN A MURINE MODEL
Lacy, J.1, Jackson, J.1, Murphy, B.1, Sharp, G.1, Devetten, M.1 1Uni-
versity of Nebraska Medical Center, Omaha, NE.
Acute Graft-versus-Host Disease (GVHD) remains a major com-
plication after allogeneic hematopoietic cell transplantation
(HCT). Several publications show a potential beneﬁcial effect of
human MMSC for the treatment of refractory GVHD. The mech-
anism of action remains to be determined. We set out to develop
an animal model that can be used to further study the effect of
MMSC on GVHD. MMSC were obtained from female C57Bl/6J
(H2b) mice by standard culture technique. ISCT criteria were used
to conﬁrm development of bona ﬁde MMSC by ﬂow cytometry
and by in-vitro differentiation experiments. GVHD was induced
by transplantation of C57Bl/6J donor bone marrow cells (5 
10E6) and spleen cells (6  10E6) into lethally irradiated DBA
(H2d) recipient mice. This model resulted in acute GVHD starting
at transplant day 10 with near-complete lethality by transplant
day 35. MMSC were infused at various doses on transplant day
10. Abrogation of GVHD was noted at all dose levels studied,
with complete rescue from lethality in the group receiving 1 
10E5 MMSC. Source of MMSC (donor, recipient, third party) did
not affect the beneﬁcial effect on GVHD. An MMSC cell line was
equally effective in providing abrogation of acute GVHD. We
conclude that a mouse model can be used to study the effect of
MMSC on acute GVHD.
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NAIVE AND MEMORY T REGULATORY CELLS RESPOND TO MESENCHY-
MAL CELLS REGULATION
Di Ianni, M.1, Del Papa, B.1, Cecchini, D.1, Moretti, L.1,
Bonifacio, E.1, De Ioanni, M.1, Bazzucchi, F.1, Zei, T.1, Sportoletti, P.1,
Falzetti, F.1, Tabilio, A.1 1Department of Clinical and Experimental
Medicine, Hematology and Clinical Immunology Section, University of
Perugia, Perugia, Italy.
In T cell replete bone marrow transplantation GvHD remains a
major problem despite prophylaxis with immune suppressive
agents. In animal models CD4()CD25()FoxP3() T regulatory
(T reg) cells protected from rejection and GvHD after bone mar-
row transplantation. 70% of T reg are memory/effector cells with
a CD45RO phenotype. The others are naive CD45RA T cell.
When sorted and/or puriﬁed both subpopulations inhibit mixed
lymphocyte cultures. T cells from healthy subjects were enriched
by immnuselection to provide populations of CD45RA cells (95
%  2.9) and CD45RO cells (97 %  0.25). Naive and memory
cells were cultured in presence of human mesenchymal cells
(hMSC) (ratio 5:1). After 7 days’ culture, in the naive population
the T reg starting fraction of 0.05 %  0.01 of CD4/CD25
positive cells, rose to 0.2 %  0.14 in presence of MSC. In the
memory population the T reg starting fraction of 0.3 %  0.05 of
CD4/CD25 positive cells, rose to 1.5 %  0.9 in the presence of
MSC. The naive T reg starting fraction expressed 3 %  1.2
CD127 which was down-regulated to 0.29 %  0.2 with MSC.
Memory T reg cells expressed CD127 in 15% 1.2 of the starting
fraction which was down-regulated to 1.32 %  0.34 with MSC.
FoxP3 expression was measured by real time quantitative PCR in
sort-puriﬁed subsets of peripheral blood, identiﬁed by staining
with a combination of CD4, CD25, CD45RA or CD45RO. FoxP3
expression increased 1.15 fold in the presence of MSC in naive T
reg and 1.14 fold in memory T reg. Observing that naive and
memory T regulatory cells respond to MSC regulation opens new
perspectives for clinical use. Post transplant infusion of MSC
and/or donor regulatory cells after co-culture with MSC might be
a new option for GvHD treatment.
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CO-TRANSPLANATION OF HAPLOIDENTICAL MESENCHYMAL STEM
CELLS TO OVERCOME GRAFT DYSFUNCTION ASSOCIATED WITH PA-
RENTAL HAPLOIDENTICAL CD34 POSTIVE SELECTED PERIPHERAL
STEM CELL GRAFTS
Ball, L.M.1, Kollen, W.J.W.1, Bernado, M.E.2, Lankester, A.1,
Roelofs, H.3, Locatelli, F.2, Fibbe, W.E.3, Egeler, R.M.1 1Dept. Pediat-
rics, Leiden University Medical Center, Leiden, RC, Netherlands;
2IRCCS Policlinico, San Matteo, Pavia, Italy; 3Immunohematology and
Stem Cell Research, Leiden University Medical Center, Leiden, RC,
Netherlands.
Transplantation with haploidentical peripheral blood stem cells
from a parent are an acceptable form of treatment for children who
require stem cell transplantation but lack a conventional donor.
However, the risk of graft dysfunction increases due to the intense
T cell depletion of CD34 positive stem cell selection. Mesenchy-
mal stem cells (MSCs) isolated from bone marrow can improve
hematological recovery but their role in overcoming graft dysfunc-
tion post transplant is unknown.
We conducted an ethically committee approved prospective
study of co-transplantation of MSCs in children undergoing haplo-
identical PBSCT.
MSCs, isolated from haploidentical parental donor marrow were
expanded under GMP conditions 4-5 weeks before transplantation.
MSCs 1-2 106/kg recipient weight (fresh or cryopreserved) were
administered i.v. 4 hours before same donor G-CSF mobilized
PBSCs. To date, 10 children have been treated in two centers.
Conditioning depended on underlying disease. No additional
GvHD prophylaxis was given. Engraftment and immune recovery
was compared to historical controls (n48).
Characteristics and results are summarized in Table 1. No failure
of donor MSC expansion was seen. No acute toxicities were ob-
served during the infusion of MSC’s. There was no difference for
gender, age, donor type, CD34 or CD3 cells infused. Com-
pared to controls (23% graft dysfunction) all patients had 100%
documented, sustained engraftment. Hematological recovery of
leucocytes was faster ([p0,008] lymphocyte  neutrophil recov-
ery). Viral reactivations commonly occurred in both patients and
controls. Acute GvHD was 12.5% in the patient group compared
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